Psigryph develops Nanopect, a sour‑cherry derived, biodegradable and non‑toxic delivery system for living cells that greatly enhances absorption so less material is required to achieve desired effects. The company plans to launch a dietary supplement called Cholestello in the U.S. in 2024. It is also developing greenhouse‑gas‑reducing biopesticides and fertilizers targeted for launch in 2026. Psigryph positions Nanopect as an environmentally friendly solution for problems in agriculture, food, and pharmaceutical industries. The company recently received $99,925 in funding to support a clinical trial for Cholestello, which it says will generate pivotal data sought by potential commercial partners. Company leadership emphasizes mission principles such as harmony with nature, long‑term thinking, and collaboration to guide product development.

Total raised

$100M

Funding rounds

1

Latest round

Equity

Latest activity

Dec 2023